SLC1A5 and neoplasm: Inhibition of glutamine uptake by an antagonist of the amino acid transporter ASCT2 (SLC1A5) promotes B7/H3 degradation through autophagy and ROS production in breast cancer cell lines, favoring the activation of tumor-infiltrating CTLs (187).